Objective To systematic review the influence of Alirocumab on clinical cardiovascular events. Methods The databases of PubMed, The Cochrane Library (volume 1, 2017), EMbase, Web of Science, CBM, WanFang Data, VIP and CNKI were retrieved with computer for searching the randomized controlled trials (RCT) related to the influence of Alirocumab on clinical cardiovascular events. The retrieving time was from database establishment time to May 2017, and retrieving methods combined MeSH subject terms and free terms. The data was given a Meta-analysis by using Stata 12.0 software. Results There were finally 9 RCT included involved 4799 patients, and 3123 in Alirocumab group and 1676 in control group. The statistical results showed that cardiac death rate was significantly decreased in Alirocumab group (RR=0.36, 95%CI: 0.14~0.93, P=0.035) compared with control group. While the difference in incidence of myocardial infarction, coronary revascularization and stroke, admission rate due to unstable angina pectoris and total incidence of clinical cardiovascular events had no statistical significance (P>0.05). Conclusion Alirocumab can reduce cardiac death rate, but has no significant superiority in reducing incidence of myocardial infarction, coronary revascularization and stroke, admission rate due to unstable angina pectoris and total incidence of clinical cardiovascular events. More RCT with higher quality are needed to further verify the above conclusion.%目的 系统评价Alirocumab对临床心血管事件的影响.方法 计算机检索PubMed、The Cochrane Library(2017年第1期)、EMbase、Web of Science、中国生物医学文献数据库(CBM)、万方(WanFang Data)、维普(VIP)、中国知网(CNKI)数据库,搜集有关Alirocumab对临床患者心血管事件影响的随机对照试验,检索时间均从建库至2017年5月.检索采用MeSH主题词和自由词相结合的方式,运用Stata 12.0软件进行Meta分析.结果 最终纳入9个RCT,共4799例患者,其中Alirocumab组3123例,对照组1676例.统计结果显示:与对照组相比,Alirocumab显著降低了心源性死亡率,差异有统计学意义(RR=0.36,95%CI:0.14~0.93,P=0.035);但在心肌梗死发生率、冠状动脉(冠脉)血运重建发生率、卒中发生率、因不稳定性心绞痛住院率以及临床总心血管事件发生率上差异无统计学意义(P>0.05).结论 Alirocumab可降低心源性死亡率,但在降低心肌梗死发生率、冠脉血运重建发生率、卒中发生率、因不稳定性心绞痛住院率以及临床总心血管事件发生率上并无明显优势.上述结论仍需更多高质量RCT加以验证.
展开▼
